Video
Dr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer
Author(s):
Matthew Galsky, MD, discusses the discordant results of the pivotal phase 3 CheckMate-274 and IMvigor010 trials of adjuvant immunotherapy in urothelial cancer.
Video Player is loading.
In an interview during the SUO 23rd Annual Meeting, Matthew Galsky, MD, discussed the pivotal phase 3 CheckMate-274 IMvigor010 trials, and the how the results of the studies yielded discordant outcomes regarding the efficacy of adjuvant immunotherapy in urothelial cancer.
Galsky is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
